Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
British Journal of Haematology, 05/11/2012
Natarajan–Ame S et al. – The addition of bortezomib to low dose cytarabine arabinoside (LDAC) in higher–risk myelodysplastic syndrome (MDS) may improve results obtained with LDAC alone, especially in patients with unfavourable karyotypes.